Qiagen (QGEN) Q2 2026 earnings review
Stagnant Top Line Masks Core Portfolio Resilience
Qiagen delivered a steady, if uninspiring, Q2. While total reported revenue was flat (0% CER), the company comfortably beat its conservative guidance for a 2% decline. The underlying engine—the five growth pillars—delivered 5% CER growth, effectively offsetting a low-teens collapse in instrument sales and the planned phase-out of the NeuMoDx portfolio. Strong automated consumables demand shielded margins, allowing adjusted EPS of $0.62 to beat expectations. Management reaffirmed full-year guidance and sketched a clear, mathematically sound bridge to a 3-4% CER growth acceleration in the second half.
🐂 Bull Case
Despite a tough capital equipment environment and a 100+ basis point margin headwind from the Parse Biosciences acquisition and FX, adjusted operating margins expanded 200 bps sequentially from Q1 to reach 29.4%.
Q2 marked the final quarter of year-over-year comparisons against the discontinued NeuMoDx and Dialunox lines. Removing this $10M anchor automatically adds roughly 2 percentage points to H2 growth.
🐻 Bear Case
Instrument sales fell at a low-teens CER rate. U.S. life sciences funding, particularly NIH outlays, remains lower YoY, forcing labs to delay system upgrades and threatening the long-term installed base expansion.
Despite management touting new GI and Meningitis panels, QIAstat-Dx sales contracted 7% CER due to tough respiratory comps, highlighting the portfolio's persistent vulnerability to seasonal flu variations.
⚖️ Verdict: ⚪
Neutral. The transition to higher-growth automation and single-cell platforms is succeeding, but reliance on a macro recovery in life science capital spending limits near-term upside. Execution is flawless, but the operating environment remains challenging.
Key Themes
Sample Tech and Automation Lead the Way
Sample Technologies emerged as the standout performer, growing 9% CER to $182 million. The strategy to migrate customers from manual to automated sample prep is bearing fruit, with automated consumables delivering high-teens CER growth. The new QIAsymphony Connect and QIAsprint Connect systems are seeing strong initial uptake, positioning the segment as the primary growth engine.
Parse Integration Outperforming
The December 2025 acquisition of Parse Biosciences is tracking ahead of its $40 million full-year 2026 sales target. By entering the high-growth single-cell analysis market with an instrument-free solution, Parse acts as a critical growth accelerant for the Sample Tech segment, overcoming the broader capital equipment spending freeze.
The H2 Acceleration Bridge
Management expects sales growth to accelerate from -1% CER in H1 to +3-4% CER in H2. The math is straightforward: a +2% boost from the roll-off of NeuMoDx/Dialunox discontinuations, +2% from recent product launches (QIAsprint, QIAstat panels), and +0.5% from Parse upside. This structural easing of comps provides a high-confidence floor for the second half.
Instrument Capex Remains Frozen (Macro)
While consumables grew in the low single-digits, total instrument sales collapsed at a low-teens CER rate. Management cited a cautious capital spending environment among U.S. Life Sciences customers, noting that NIH outlays for H1 2026 remain lower than H1 2025. This poses a long-term risk: without placing new boxes today, future consumable streams will stall.
QIAstat-Dx Respiratory Drag Contradicts Menu Narrative
Management heavily promoted the menu expansion of QIAstat-Dx (GI and Meningitis panels). However, the hard data contradicts the rosy narrative: the segment's sales actually fell 7% CER to $32 million. Despite new panels, QIAstat-Dx remains overwhelmingly tethered to respiratory testing comps (roughly 65% of syndromic volume), exposing the segment to significant seasonal volatility.
China Weakness Persists
The Asia Pacific region declined 2% CER, dragged down entirely by China, which posted a low-teens decline. While China now represents only ~4% of total sales, the total lack of recovery acts as a persistent anchor on overall APAC performance, partially neutralizing high-teens growth in markets like Japan.
Other KPIs
Decelerating YoY from 29.9% in Q2 2025, but accelerating sequentially from 27.4% in Q1 2026. The company successfully absorbed the margin-dilutive impact of the Parse acquisition and adverse FX movements by aggressively managing Sales & Marketing expenses (down to 21.8% of sales from 22.1%).
Slightly below the $217 million generated in H1 2025. Operating cash flow was flat at $301 million despite $20 million in restructuring payments and an intentional inventory build (Days Inventory Outstanding increased to 153 days) to support upcoming product launches like QIAmini.
Reversing. Down 8% CER. While the flagship QIAcuity digital PCR system grew double-digits via strong consumables demand, the segment as a whole was dragged into negative territory by significantly weaker OEM demand from third-party partners.
Guidance
Accelerating from 0% CER in Q2. Management expects a 1 percentage point negative FX impact, bringing reported growth closer to flat.
Stable sequentially compared to Q2 2026, and a slight acceleration from the $0.61 delivered in Q3 2025.
Stable. The reaffirmed full-year guidance mathematically requires H2 growth to step up to the 3-4% CER range to compensate for the -1% CER contraction experienced in H1.
Stable. Fully reaffirmed. FX is expected to have a neutral impact on full-year adjusted EPS.
Key Questions
QIAstat-Dx Growth Floor
With QIAstat-Dx down 7% this quarter due to respiratory comps, at what point will the non-respiratory panels (GI, Meningitis, upcoming BCID) constitute a large enough share of the mix to insulate the segment from seasonal flu weakness?
Capital Equipment Visibility
You noted a sequential improvement in Q2 U.S. life science funding despite NIH outlays being lower YoY. Are you seeing actual pipeline growth for larger capital purchases going into Q4, or is the H2 acceleration solely dependent on consumables?
Parse Biosciences Upside
Parse is tracking ahead of the $40 million target. How much of this outperformance is coming from legacy customers scaling up usage versus net new customer acquisitions won from competitors like 10x Genomics?
OEM Weakness
PCR sales declined 8% largely due to third-party OEM demand. Is this OEM weakness a temporary inventory destocking issue at your partners, or a structural loss of market share?